We’ll see you in six months.
What is OCREVUS?
OCREVUS is a prescription medication for multiple sclerosis.
Multiple Sclerosis treatment with OCREVUS helps with the signs and symptoms of both Relapsing forms of Multiple Sclerosis (RMS) and Primary Progressive Multiple Sclerosis (PPMS).
OCREVUS has shown promising results in:
• Reducing the frequency of RMS relapses.
• Slowing the overall progression of RMS and PPMS.
• Slowing the worsening of multiple sclerosis symptoms in both RMS and PPMS.
OCREVUS also leaves you free to get on with life between MS treatments – after the first dose, you’ll only need to take it every six months.
Helpful patient resources
OCREVUS is available in 2 ways
- OCREVUS SC (subcutaneous) is given by an injection under the skin
- OCREVUS IV (intravenous) is given by an infusion into the vein
OCREVUS IV is PHARMAC funded
OCREVUS IV is PHARMAC funded for people with RRMS and PPMS who meet pre-defined criteria.
OCREVUS SC is not PHARMAC funded.
If you would like more information please contact Roche Products (New Zealand) Ltd. on freephone 0800 656 464
OCREVUS is not suitable for everyone, so it is important that you discuss with your doctor or nurse whether this medicine is right for you.
Multiple Sclerosis Society of New Zealand
The MSNZ mission is to advocate for people with MS in New Zealand to have access to first world treatment, resources and services to improve their well-being and quality of life.
For more information and to contact your local Multiple Sclerosis support office, go to www.msnz.org.nz/contact-your-regional-society/